NVO vs ROG

For growth investors, Novo Nordisk A/S (NVO) is the stronger pick with 6.

4% revenue growth year-over-year, versus -2. 3% for Rogers Corporation (ROG). Novo Nordisk A/S (NVO) offers the better valuation at 12. 7x trailing P/E (2. 1x forward), making it the more compelling value choice. Analysts rate Novo Nordisk A/S (NVO) a "Buy" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Novo Nordisk A/S is actually cheaper at 2.

1x.

Over the past 5 years, Novo Nordisk A/S (NVO) delivered a total return of +39.

0%, compared to -26. 4% for Rogers Corporation (ROG). Over 10 years, the gap is even starker: ROG returned +122. 4% versus NVO's +105. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Rogers Corporation (ROG) is the lower-risk stock at 1.

24β versus Novo Nordisk A/S's 1. 56β — meaning NVO is approximately 26% more volatile than ROG relative to the S&P 500. On balance sheet safety, Rogers Corporation (ROG) carries a lower debt/equity ratio of 3% versus 67% for Novo Nordisk A/S — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novo Nordisk A/S (NVO) is pulling ahead at 6.

4% versus -2. 3% for Rogers Corporation (ROG). On earnings-per-share growth, the picture is similar: Novo Nordisk A/S grew EPS 1. 8% year-over-year, compared to -340. 0% for Rogers Corporation. Over a 3-year CAGR, NVO leads at 20. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus -7. 6% for Rogers Corporation — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVO leads at 41. 3% versus 6. 4% for ROG. At the gross margin level — before operating expenses — NVO leads at 81. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Novo Nordisk A/S (NVO) trades at 2.

1x forward P/E versus 38. 6x for Rogers Corporation — 36. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ROG: 6. 7% to $150. 00.

In this comparison, NVO (4.

0% yield) pays a dividend. ROG does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novo Nordisk A/S (NVO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (4.

0% yield, +105. 1% 10Y return). Both have compounded well over 10 years (NVO: +105. 1%, ROG: +122. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NVO (Healthcare) and ROG (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NVO is a large-cap deep-value stock; ROG is a small-cap quality compounder stock. NVO pays a dividend while ROG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.